Acute Care Volume 24, Issue 9

Medication Safety Alert! May 9, 2019

In this week's issue:

  • As Approval of Medical Cannabis Spreads State by State, Product Labeling Improvements Are a Must
  • Payer-driven biosimilar requirements: New risks in patients with cancer and chronic diseases
  • Sidebar: Example of labeling issues with medical cannabis
  • Fasting during Ramadan and safe drug administration
  • A mitoMYcin-mitoXANTRONE mix-up
Featured article

Problem: Anecdotal support, public opinion, and state laws in the US are outpacing scientific research involving medical marijuana, more professionally known as medical cannabis. Medical cannabis differs from the street product in that the plant must be reliably grown and handled in a manner that resembles good manufacturing practices. This allows growers to assay and establish the products’ contents with the intent of passing that information on to dispensaries and patients. However, lack of federal regulation has allowed for heterogeneity of state programs, yielding a wide variety of...

Access this Newsletter

Purchasing Options

Purchase access to this individual issue

Purchase a year's access to this bi-weekly publication (25 issues)